Theravance (NASDAQ:THRX) will report earnings after markets close on Thursday, April 25th. Theravance, Inc. is a biopharmaceutical company that discovers, develops, and markets small molecule medicines for unmet medical needs across a number of therapeutic areas including respiratory disease, bacterial infections, and gastrointestinal disorders.
Here is your Cheat Sheet to Theravance Earnings:
Earnings Expectations: Analysts expect earnings of $-0.34 per share on revenues of $5.12 million.
Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a loss of $0.08 to a loss $0.48. For the current year, the average estimate is a loss of $2.4, which is worse than the estimate ninety days ago.
Here’s how Theravance has been performing on an annual basis:
|Revenue ($) in millions||23.10||24.37||24.22||24.51||135.76|
|Diluted EPS ($)||-1.53||-1.35||-1.16||-1.41||-0.20|
Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:
|Quarter||Dec. 31, 2011||Mar. 31, 2012||Jun. 30, 2012||Sep. 30, 2012||Dec. 31, 2012|
|Revenue ($) in millions||5.36||127.10||1.43||1.43||5.80|
|Diluted EPS ($)||-0.45||0.93||-0.42||-0.37||-0.34|
Theravance has beat analyst estimates 4 times in the past four quarters. Shareholders could expect a boost if the company beats estimates.
“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)